Taysha Gene Therapies, Inc. TSHA Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $0-100% | $5.49M— | $0-100% | $1.99M-13.7% | $2.3M+13.8% | ||
| $33.81M+35.5% | $24.95M-3.1% | $25.75M+27.8% | $20.14M+29.4% | $15.57M+1.6% | ||
| $9.68M+9.6% | $8.83M+6.7% | $8.28M-3.7% | $8.6M+5.4% | $8.16M+23.1% | ||
| $43.49M+28.7% | $33.79M-0.7% | $34.02M+18.4% | $28.74M+21.1% | $23.72M+8.1% | ||
| -$43.49M-53.7% | -$28.3M+16.8% | -$34.02M-27.2% | -$26.75M-24.9% | -$21.42M-7.5% | ||
| $9K-25.0% | $12K-20.0% | $15K-11.8% | $17K-10.5% | $19K-13.6% | ||
| $1.08M+140% | $449K-65.2% | $1.29M+1,101% | -$129K-19.4% | -$108K-109% | ||
| -$42.41M-52.3% | -$27.85M+14.9% | -$32.73M-21.8% | -$26.88M-24.9% | -$21.53M-14.6% | ||
| -$0.12-50.0% | -$0.08+11.1% | -$0.090.0% | -$0.09-12.5% | -$0.08-14.3% | ||
| -$43.19M-54.2% | -$28M+17.2% | -$33.82M-27.9% | -$26.45M-25.1% | -$21.14M-7.7% | ||
| -$43.49M-53.7% | -$28.3M+16.8% | -$34.02M-27.2% | -$26.75M-24.9% | -$21.42M-7.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Taysha Gene Therapies, Inc.'s revenue?
- Taysha Gene Therapies, Inc. (TSHA) generated $7.5M in revenue over the trailing twelve months, up 3.4% year over year.
- Is Taysha Gene Therapies, Inc. profitable?
- Taysha Gene Therapies, Inc. is not currently profitable: it reported a net loss of $129.9M over the trailing twelve months, a -1738.4% net margin.
- What is Taysha Gene Therapies, Inc.'s earnings per share?
- Taysha Gene Therapies, Inc.'s diluted EPS over the trailing twelve months is $-0.38.
- Where does Taysha Gene Therapies, Inc.'s income statement data come from?
- Every line is extracted from Taysha Gene Therapies, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
